2 ASX healthcare shares that have risen since Pfizer's vaccine news

The market-moving COVID-19 vaccine announcement from Pfizer has put the spotlight back on ASX healthcare shares.

| More on:
Doctor holding small world globe in one hand and a Covid vaccine needle in the other

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 Index (ASX: XJO) has risen by 4.67% since last Friday's close (6 November) to 6,466 points. Global investors have snapped up pandemic-hit shares after Pfizer Inc. (NYSE: PFE) indicated that its COVID-19 vaccine had proved more than 90% effective in its trial.

A breakthrough COVID-19 vaccine

On Monday, the American drug maker Pfizer and its German partner BioNTech SE (NASDAQ: BNTX) released positive results from the clinical trial of their COVID-19 vaccine, BNT162b2. Pfizer's chair and CEO Dr. Albert Bourla commented:

Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent COVID-19.

Acting Victorian chief health officer Professor Allan Cheng commented that while the Pfizer vaccine was good news, there was "very little detail about what the results actually are," as they have not been published in a peer-reviewed medical journal (as quoted by The Guardian).

Despite the lack of detail, investors are starting to look at the healthcare sector again. Here are 2 ASX healthcare shares that have gained traction since the anouncement.

Mayne Pharma Group (ASX: MYX)

Mayne Pharma is a specialty pharmaceutical company focused on applying its expertise in drug delivery to commercialise pharmaceutical products. The company's flagship product TOLSURA is used for the treatment of infectious pulmonary and extrapulmonary diseases.

In its FY20 results presentation in August, Mayne Pharma reported revenue of $457 million and underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) of $95 million, including a non-cash intangible asset impairment of $99 million.

Meanwhile, the company reported that TOLSURA sales  grew by 460% in the fourth quarter year over year, due to the COVID-19 pandemic. Mayne expects the sales of TOLSURA to accelerate in FY21.

The Mayne share price has gone up 6.66% since last Friday's close, valuing the company at a market capitalisation of $537 million. 

Medical Developments International Ltd (ASX: MVP)

This Australian healthcare company manufactures and distributes pharmaceutical drugs and medical equipment and has a market capitalisation of $419 million. The Medical Developments share price has risen by 14% since last Friday.

According to its FY20 report, Medical Development International grew sales by 61%, an all-time record, with Australian sales up by 43% and North American sales up by 88%. 

Finally, the company's management team has also indicated their intention to replicate the success of the respiratory business internationally. This is achieved by buying back the European distribution rights to its Penthrox methoxyflurane inhaler from Mundipharma for 3 million euros.

Penthrox is the company's pain relief product and is approved throughout Europe, with 568 European Union organisations buying the product. The company has indicated it is focused on taking a more direct role in the commercialisation of Penthrox by building a direct in-market presence in Europe.

MWUaus has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

ASX healthcare stock surges 11% on 'incredibly valuable' FDA news

Some big news is getting investors excited on Tuesday. What's happening?

Read more »

A man thinks very carefully about his money and investments.
Healthcare Shares

How much could $10,000 invested in CSL shares be worth next year?

Do analysts think it would be worth sinking money into this top stock?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

This ASX All Ords stock is rocketing 20% after accepting a takeover offer

These two diagnostics companies are planning to merge their operations.

Read more »

A man sleeps in a bed with white sheets while holding a teddy bear and a smile on his face.
Healthcare Shares

Buy the ASX 200 healthcare stock with 'decades of growth ahead'

This healthcare giant is well positioned for growth, experts say.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Telix Pharmaceuticals share price sinks on unexpected Nasdaq news

ASX 200 investors are bidding down the Telix Pharmaceuticals share price today. But why?

Read more »

Health workers shake hands and congratulate each other on good news.
Healthcare Shares

This ASX 200 healthcare stock is up 48% in a year, but one director is still buying!

A director of this ASX 200 healthcare company has just lifted his personal stake by 50%.

Read more »

A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts
Healthcare Shares

Why this broker just upgraded Telix shares to a buy rating

Bell Potter thinks a recent pullback has created a buying opportunity.

Read more »

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
Healthcare Shares

Sigma share price dives 6% on Chemist Warehouse merger hurdle

The proposed merger faces ACCC concerns.

Read more »